TargetBeta
HTR2C
5-hydroxytryptamine receptor 2C · also 5-HT2C, 5HTR2C, HTR1C · 5-hydroxytryptamine receptors, G protein-coupled
5 programs in company-led studies act on HTR2C, from 5 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cyclobenzaprinerule | Tonix Pharmaceuticals | phase 4 | 322 running | HTR2A | ChEMBL |
| Risperidonerule | Johnson & Johnson | phase 4 | 1111 running | DRD2, HTR2A | ChEMBL |
| Olanzapinerule | Eli Lilly | phase 4 | 761 running | DRD2, DRD3, DRD4, HTR2A | ChEMBL |
| Fenfluraminerule | UCB | phase 3 | 112 running | HTR1D, SIGMAR1 | ChEMBL |
| Trazodonerule | Angelini Pharma | phase 3 | 140 running | HTR2A, SLC6A4 | ChEMBL |
Conditions their studies are in
- Bipolar Disorder, 2 programs
- Depressive Disorder, Major, 2 programs
- Schizophrenia, 2 programs
- Autistic Disorder, 1 program
- Borderline Personality Disorder, 1 program
- Dementia, 1 program
- Depression, 1 program
- Depressive Disorder, Treatment-Resistant, 1 program
- Diabetic Neuropathies, 1 program
- Epilepsies, Myoclonic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 8, 2027Fenfluramine · UCB · phase 3 · NCT05064878
- Dec 2027Risperidone · Johnson & Johnson · phase 4 · NCT07565428
- Dec 2027Olanzapine · Eli Lilly · phase 4 · NCT07565428
- Feb 2028cyclobenzaprine · Tonix Pharmaceuticals · phase 4 · NCT07621237
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.